Clinical Trial Update: A Study of Potential Treatment-Responsive Biomarkers and Clinical Outcomes in Hunter Syndrome

View source ↗

Summary

Denali Therapeutics completed a clinical trial in Mucopolysaccharidosis type II investigating potential treatment-responsive biomarkers and clinical outcomes.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Mucopolysaccharidosis Type Ii

Snippet

Sponsor: Denali Therapeutics Inc. | Conditions: Mucopolysaccharidosis II | Status: COMPLETED